MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences, Inc. - Common Stock (NQ:ALPN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alpine Immune Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance. 
Via Benzinga
News headline image
Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 50 points on Thursday. Shares of Alaska Air Group, Inc. (NYSE: ALK) rose during Thursday’s session following upbeat earnings. 
Via Benzinga
Topics Stocks
News headline image
Beyond The Numbers: 7 Analysts Discuss Alpine Immune Sciences Stock ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Alpine Immune Sciences ↗
 
Via Benzinga
News headline image
Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
What 8 Analyst Ratings Have To Say About Alpine Immune Sciences ↗
 
Via Benzinga
News headline image
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
News headline image
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Proposed Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
The Benzinga Stock Whisper Index uses proprietary data to look at stocks with increased interest from investors. 
Via Benzinga
News headline image
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Apple, Coinbase Global, Fortinet And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Is Alpine Immune Sciences Stock Trading Higher Today? ↗
Alpine Immune Sciences Inc (NASDAQ: ALPN) presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking session at the American Society of Nephrology  
Via Benzinga
News headline image
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023 ↗
 
Via Benzinga
News headline image
Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
IgAN Treatment Market Worth Over $6B By 2032: Analyst Bearish On Povetacicept's Promising Role ↗
RBC Capital Markets initiated coverage on Alpine Immune Sciences Inc (NASDAQ: ALPN), noting that the autoimmune disease market (over $165 billion) is meaningful for the company's lead candidate -... 
Via Benzinga
News headline image
Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story